Stabil Koroner Arter Hastalığı Olan Şizofreni Hastalarında Monosit/Yüksek Yoğunluklu Lipoprotein (MHR) Oranının Öngördürücülüğü

Year 2022, , 77 - 83, 28.02.2022

Mustafa Candemir , Alparslan Cansız

https://doi.org/10.54005/geneltip.1032165

Cited By: 1

Abstract

Amaç: Bu çalışmada stabil koroner arter hastalığı olan şizofreni hastalarında (SKAH-Ş) monosit/yüksek yoğunluklu lipoprotein oranının (MHO) tanıda öngördürücü değerinin olup olmadığını araştırmayı amaçladık.
Gereç ve yöntem: Bu kesitsel çalışmaya toplam 281 katılımcı alındı. Katılımcıların 85'ine şizofreni ve stabil koroner arter hastalığı (Grup 1), 92'sine ise sadece şizofreni (Grup 2) tanısı konuldu. Kontrol grubundaki 104 katılımcının (Grup 3) ise hiçbir hastalığı yoktu.
Bulgular: MHO grup 1'de en yüksek iken grup 2'de grup 3'e göre daha yüksekti (grup 1: 18.91 (13.38-23.60); grup 2: 13.68 (11.11-16.66); grup 3: 12.50 (9.13-15.68); her iki karşılaştırma için p <0.001). Buna zıt olarak, HDL grup 1'de en düşük iken grup 2'de grup 3'e göre daha düşüktü (grup 1: 38.52 ± 9.45; grup 2: 42.76 ± 9.12; grup 3: 47.00 ± 11.87; her iki karşılaştırma için p <0.05). MHO'nun kesme puanı stabil koroner arter hastalığı olan şizofreni hastalarında 12.77 ve üzeri alındığında duyarlılık %79, özgüllük ise %43 bulundu. Sadece şizofreni hastalarında ise kesme değeri 10.73 ve üzeri alındığında duyarlılık % 79, özgüllük ise % 50 bulundu.
Sonuç: Artmış inflamasyon ve oksidatif stresi gösteren yüksek MHO, şizofreni ve stabil koroner arter hastalığı olan şizofreni hastalarında önemli ve bağımsız bir belirteç olarak bulundu.

Keywords

Koroner arter hastalığı, şizofreni, monosit/yüksek yoğunluklu lipoprotein oranı, inflamasyon, oksidatif stres

Supporting Institution

yok

Project Number

yok

Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease

Abstract

Aim: We aimed to investigate whether monocyte/high density lipoprotein ratio (MHR) has a predictive value in patients with schizophrenia (SP) and in schizophrenia patients with stable coronary artery disease (SPCAD).
Material and Method: A total of 281 participants were enrolled in this cross-sectional study. Of the participants, 85 (Group 1) were diagnosed schizophrenia and stable coronary artery disease, and 92 (Group 2) were diagnosed only schizophrenia. 104 (Group 3) participants in the control group had no disease.
Results: MHR was highest in group 1 and higher in group 2 than in group 3 (18.91 (13.38-23.60) vs. 13.68 (11.11-16.66) vs. 12.50 (9.13-15.68), respectively; p<0.001 for both). Conversely, HDL was the lowest in group 1, while it was lower in group 2 than in group 3 (38.52 ± 9.45 vs. 42.76 ± 9.12 vs. 47.00 ± 11.87, respectively p<0.05 for both). The cutoff value of MHR for SPCAD was 12.77, with a sensitivity of 79% and a specificity of 43%. This value for SP was 10.73, with a sensitivity of 79% and a specificity of 50%.
Conclusion: High MHR which indicates an enhanced inflammation and oxidative stress was found to be a significant and independent marker in SP and SPCAD.

Keywords

schizophrenia, Coronary artery disease, monocyte to high-density lipoprotein ratio, inflammation, oxidative stress

Project Number

yok

References

• McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-An Overview. JAMA psychiatry. 2019:1-10.
• Liu J, Li M, Luo XJ, Su B. Systems-level analysis of risk genes reveals the modular nature of schizophrenia. Schizophrenia research. 2018;201:261-9.
• Trépanier MO, Hopperton KE, Mizrahi R, Mechawar N, Bazinet RP. Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Molecular psychiatry. 2016;21:1009-26.
• Gallego JA, Blanco EA, Husain-Krautter S, et al. Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta-analysis. Schizophrenia research. 2018;202:64-71.
• Karageorgiou V, Milas GP, Michopoulos I. Neutrophil-to-lymphocyte ratio in schizophrenia: A systematic review and meta-analysis. Schizophrenia research. 2019;206:4-12.
• Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biological psychiatry. 2013;74:400-9.
• Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological psychiatry. 2011;70:663-71.
• Guest PC. Insulin Resistance in Schizophrenia. Advances in experimental medicine and biology. 2019;1134:1-16.
• Leonard BE, Schwarz M, Myint AM. The metabolic syndrome in schizophrenia: is inflammation a contributing cause? Journal of psychopharmacology (Oxford, England). 2012;26:33-41.
• Karanikas E, Antoniadis D, Garyfallos GD. The role of cortisol in first episode of psychosis: a systematic review. Current psychiatry reports. 2014;16:503.
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. The New England journal of medicine. 2005;352:1685-95.
• Ancuta P, Wang J, Gabuzda D. CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. Journal of leukocyte biology. 2006;80:1156-64.
• Hansson GK. Inflammatory mechanisms in atherosclerosis. Journal of thrombosis and haemostasis : JTH. 2009;7 Suppl 1:328-31.
• Kuvin JT, Rämet ME, Patel AR, et al. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. American heart journal. 2002;144:165-72.
• Kuvin JT, Patel AR, Sidhu M, et al. Relation between high-density lipoprotein cholesterol and peripheral vasomotor function. The American journal of cardiology. 2003;92:275-9.
• Soria-Florido MT, Schröder H, Grau M, Fitó M, Lassale C. High density lipoprotein functionality and cardiovascular events and mortality: A systematic review and meta-analysis. Atherosclerosis. 2020;302:36-42.
• Wang P, Wang Y, Ma W, Li H, Chen H. High-density lipoprotein cholesterol and intracoronary thrombosis burden. Coronary artery disease. 2013;24:1-5.
• Karataş MB, Çanga Y, Özcan KS, et al. Monocyte to high-density lipoprotein ratio as a new prognostic marker in patients with STEMI undergoing primary percutaneous coronary intervention. The American journal of emergency medicine. 2016;34:240-4.
• Wu TT, Zheng YY, Chen Y, et al. Monocyte to high-density lipoprotein cholesterol ratio as long-term prognostic marker in patients with coronary artery disease undergoing percutaneous coronary intervention. Lipids in health and disease. 2019;18:180.
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2019;41:407-77.
• Sekar A, Bialas AR, de Rivera H, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530:177-83.
• Mazza MG, Capellazzi M, Lucchi S, et al. Monocyte count in schizophrenia and related disorders: a systematic review and meta-analysis. Acta neuropsychiatrica. 2020;32:229-36.
• Weber NS, Gressitt KL, Cowan DN, et al. Monocyte activation detected prior to a diagnosis of schizophrenia in the US Military New Onset Psychosis Project (MNOPP). Schizophrenia research. 2018;197:465-9.
• Misiak B, Stańczykiewicz B, Łaczmański Ł, Frydecka D. Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: A systematic review and meta-analysis. Schizophrenia research. 2017;190:18-27.
• Douglas J, Nasrallah HA. Low high-density lipoprotein and psychopathology: A review. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 2019;31:209-13.
• Johnsen SH, Fosse E, Joakimsen O, et al. Monocyte count is a predictor of novel plaque formation: a 7-year follow-up study of 2610 persons without carotid plaque at baseline the Tromsø Study. Stroke. 2005;36:715-9.
• Afiune Neto A, Mansur Ade P, Avakian SD, Gomes EP, Ramires JA. [Monocytosis is an independent risk marker for coronary artery disease]. Arquivos brasileiros de cardiologia. 2006;86:240-4.
• Bath PM, Gladwin AM, Martin JF. Human monocyte characteristics are altered in hypercholesterolaemia. Atherosclerosis. 1991;90:175-81.
• Murphy AJ, Chin-Dusting JP, Sviridov D, Woollard KJ. The anti inflammatory effects of high density lipoproteins. Current medicinal chemistry. 2009;16:667-75.
• Murphy AJ, Woollard KJ. High-density lipoprotein: a potent inhibitor of inflammation. Clinical and experimental pharmacology & physiology. 2010;37:710-8.
• Açıkgöz SK, Açıkgöz E, Şensoy B, Topal S, Aydoğdu S. Monocyte to high-density lipoprotein cholesterol ratio is predictive of in-hospital and five-year mortality in ST-segment elevation myocardial infarction. Cardiology journal. 2016;23:505-12.
• Yvan-Charvet L, Pagler T, Gautier EL, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science (New York, NY). 2010;328:1689-93.
• Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arteriosclerosis, thrombosis, and vascular biology. 1995;15:1987-94.
• Barter P. The role of HDL-cholesterol in preventing atherosclerotic disease. European Heart Journal Supplements. 2005;7(suppl_F):F4-F8.
• Roberts CK, Ng C, Hama S, Eliseo AJ, Barnard RJ. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. Journal of applied physiology (Bethesda, Md : 1985). 2006;101:1727-32.
• Ringen PA, Engh JA, Birkenaes AB, Dieset I, Andreassen OA. Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. Frontiers in psychiatry. 2014;5:137.
• von Hausswolff-Juhlin Y, Bjartveit M, Lindström E, Jones P. Schizophrenia and physical health problems. Acta psychiatrica Scandinavica Supplementum. 2009:15-21.
• Onen S, Taymur I. Evidence for the atherogenic index of plasma as a potential biomarker for cardiovascular disease in schizophrenia. Journal of psychopharmacology (Oxford, England). 2021;35:1120-6.